Datroway (datopotamab deruxtecan)

news

AstraZeneca and Daiichi’s Datroway gets phase III breast cancer boost

6 October 2025 | By Dominic Tyer (European Pharmaceutical Review)

Companies’ first-line ambitions for the antibody drug conjugate buoyed by the TROPION-Breast02 clinical trial.

news

CHMP meeting highlights – January 2025

3 February 2025 | By Catherine Eckford (European Pharmaceutical Review)

In its January meeting, the EMA’s human medicines committee recommended eight new medicines, including biosimilars and a new vaccine.

article

Antibody-drug conjugates: paving the future of oncology clinical development

26 October 2023 | By Catherine Eckford (European Pharmaceutical Review), Dr Mark Rutstein (Daiichi Sankyo)

Dr Mark Rutstein, Senior Vice President, Head of Oncology Clinical Development at Daiichi Sankyo, highlights key data about the company’s antibody-drug conjugate (ADC) being investigated for breast and lung cancer, and shares insight into why ADCs could replace current standards of care in oncology.